Microba Life Sciences Inkomsten in het verleden
We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf
Verleden criteriumcontroles 0/6
Microba Life Sciences's earnings have been declining at an average annual rate of -24.4%, while the Healthcare industry saw earnings declining at 3.3% annually. Revenues have been growing at an average rate of 28.3% per year.
Belangrijke informatie
-24.4%
Groei van de winst
-0.7%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 2.4% |
| Inkomstengroei | 28.3% |
| Rendement op eigen vermogen | -48.4% |
| Nettomarge | -164.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Microba Life Sciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 12 | -20 | 15 | 11 |
| 31 Mar 24 | 9 | -19 | 13 | 12 |
| 31 Dec 23 | 7 | -18 | 11 | 13 |
| 30 Sep 23 | 6 | -16 | 10 | 11 |
| 30 Jun 23 | 5 | -13 | 10 | 9 |
| 31 Mar 23 | 5 | -12 | 10 | 8 |
| 31 Dec 22 | 5 | -11 | 10 | 6 |
| 30 Sep 22 | 5 | -11 | 10 | 6 |
| 30 Jun 22 | 5 | -11 | 10 | 5 |
| 31 Mar 22 | 4 | -11 | 9 | 5 |
| 31 Dec 21 | 4 | -11 | 9 | 4 |
| 30 Sep 21 | 4 | -9 | 8 | 3 |
| 30 Jun 21 | 4 | -8 | 7 | 2 |
| 30 Jun 20 | 3 | -7 | 7 | 0 |
| 30 Jun 19 | 2 | -5 | 4 | 0 |
Kwaliteitswinsten: MAP is currently unprofitable.
Groeiende winstmarge: MAP is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MAP is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Versnelling van de groei: Unable to compare MAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: MAP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-25.4%).
Rendement op eigen vermogen
Hoge ROE: MAP has a negative Return on Equity (-48.38%), as it is currently unprofitable.